Cognitive Biases and Socio-Occupational Functioning Mediate the Relationship between Executive Functions and the Severity of Psychopathology among Young Adults with Psychotic-like Experiences: 1-Year Follow-Up Study.

Aleksandra Arciszewska-Leszczuk, Andrzej Cechnicki, Dorota Frydecka, Dawid Kruk, Łukasz Gawęda
Author Information
  1. Aleksandra Arciszewska-Leszczuk: Faculty of Psychology, University SWPS, 81-745 Sopot, Poland. ORCID
  2. Andrzej Cechnicki: Department of Community Psychiatry, Jagiellonian University Medical College, 31-115 Krakow, Poland.
  3. Dorota Frydecka: Department of Psychiatry, Wroclaw Medical University, 50-367 Wroclaw, Poland. ORCID
  4. Dawid Kruk: Department of Community Psychiatry, Jagiellonian University Medical College, 31-115 Krakow, Poland.
  5. Łukasz Gawęda: Experimental Psychopathology Lab, Institute of Psychology, Polish Academy of Sciences, 00-378 Warsaw, Poland.

Abstract

The aim of this study was to investigate whether Trail Making Test (TMT) performance is associated with the severity of psychopathological symptoms related to psychosis among young adults with elevated level of Psychotic-like Experiences (PLEs), and whether this relationship is mediated by cognitive biases and socio-occupational functioning. A total of 187 subjects from a larger population of 6722 young adults participated in this 1-year follow-up study. The inclusion criteria were an elevated level of PLEs (the highest score of the Prodromal Questionnaire) and a lack of schizophrenia diagnosis. Eventually, 134 subjects (71.6%) completed the TMT, as well as the DACOBS scale (cognitive biases), at baseline and were examined twice using the CAARMS (Psychopathology) and SOFAS (socio-occupational functioning) scales. In the first (I) and second (II) measurements, the calculated effects indicate indirect-only mediations, which explained 35 and 38% of the variance of the CAARMS. The TMT B execution time was positively associated with the DACOBS scale (β = 0.19, = 0.028), which was negatively related to the SOFAS I (β = -0.37, < 0.001) and SOFAS II (β = -0.20, = 0.016) measurements. A lower score on the SOFAS I predicted a higher score on the CAARMS I (β = -0.50, < 0.001), and a lower SOFAS II predicted a higher score on the CAARMS II (β = -0.61, < 0.001). Subtle EF dysfunctions may, over time, translate into a greater severity of symptoms related to psychosis in people with elevated PLEs, and this is mediated by a deterioration of their metacognition and socio-occupational functioning.

Keywords

References

  1. Front Psychiatry. 2023 Jan 18;13:1081620 [PMID: 36741560]
  2. Psychol Med. 2019 Jul;49(10):1589-1599 [PMID: 31088578]
  3. JAMA Psychiatry. 2018 Sep 1;75(9):929-939 [PMID: 30046827]
  4. Aust N Z J Psychiatry. 2015 Jan;49(1):24-35 [PMID: 25430911]
  5. Am J Psychiatry. 2020 Apr 1;177(4):308-317 [PMID: 31906710]
  6. JAMA Psychiatry. 2020 Jul 1;77(7):755-765 [PMID: 32159746]
  7. Early Interv Psychiatry. 2012 Aug;6(3):300-8 [PMID: 22029711]
  8. Psychol Serv. 2022;19(Suppl 1):120-138 [PMID: 35286123]
  9. Schizophr Res. 2011 Nov;132(2-3):213-9 [PMID: 21907547]
  10. Schizophr Res. 2010 Dec;124(1-3):169-75 [PMID: 20800998]
  11. Schizophr Bull. 2003;29(4):703-15 [PMID: 14989408]
  12. Occup Environ Med. 2005 Feb;62(2):105-12 [PMID: 15657192]
  13. Neuropsychologia. 2011 Jan;49(2):203-8 [PMID: 21095198]
  14. Psychopathology. 2000 Jan-Feb;33(1):48-51 [PMID: 10601828]
  15. J Neuropsychiatry Clin Neurosci. 2011 Fall;23(4):457-60 [PMID: 22231319]
  16. Front Psychiatry. 2015 Jun 01;6:79 [PMID: 26082726]
  17. Front Psychiatry. 2021 Aug 09;12:700747 [PMID: 34434128]
  18. Psychol Med. 2012 Nov;42(11):2239-53 [PMID: 22260930]
  19. J Clin Exp Neuropsychol. 2000 Aug;22(4):518-28 [PMID: 10923061]
  20. Schizophr Res. 2002 Mar 1;54(1-2):59-65 [PMID: 11853979]
  21. Schizophr Bull. 2006 Jan;32(1):179-94 [PMID: 16166612]
  22. Schizophr Res. 2013 Mar;144(1-3):63-71 [PMID: 23332365]
  23. Health Commun. 2019 Jan;34(1):118-124 [PMID: 29053380]
  24. Schizophr Bull. 2014 Nov;40(6):1452-61 [PMID: 24550526]
  25. J Int Neuropsychol Soc. 2018 Oct;24(9):905-916 [PMID: 30375321]
  26. J Abnorm Psychol. 1977 Apr;86(2):103-26 [PMID: 858828]
  27. Schizophr Bull. 1984;10(2):300-12 [PMID: 6729414]
  28. Schizophr Res. 2007 Jul;93(1-3):350-4 [PMID: 17467957]
  29. Eur Psychiatry. 2011 Sep;26(6):396-401 [PMID: 21334860]
  30. Front Psychiatry. 2021 Mar 19;12:639536 [PMID: 33815171]
  31. Schizophr Res. 2020 Aug;222:10-22 [PMID: 32595098]
  32. Neuropsychol Rev. 2018 Dec;28(4):509-533 [PMID: 30343458]
  33. Psychiatr Serv. 2003 Aug;54(8):1129-35 [PMID: 12883141]
  34. Schizophr Bull. 2006 Apr;32(2):352-9 [PMID: 16254060]
  35. Early Interv Psychiatry. 2022 Jul;16(7):724-735 [PMID: 34528404]
  36. J Psychiatr Res. 2021 Dec;144:8-13 [PMID: 34592511]
  37. Psychol Med. 2009 Feb;39(2):179-95 [PMID: 18606047]
  38. Brain Cogn. 2012 Jun;79(1):60-9 [PMID: 22342280]
  39. Schizophr Res. 2007 Mar;91(1-3):246-53 [PMID: 17239566]
  40. Biol Psychiatry. 2008 Nov 1;64(9):782-8 [PMID: 18597738]
  41. Schizophr Res Cogn. 2022 Apr 26;29:100254 [PMID: 35521291]
  42. Epidemiol Psychiatr Sci. 2019 Oct;28(5):532-543 [PMID: 29656729]
  43. Curr Pharm Des. 2012;18(4):399-415 [PMID: 22239571]
  44. Br J Clin Psychol. 2007 Jun;46(Pt 2):155-73 [PMID: 17524210]
  45. Schizophr Res. 2014 Sep;158(1-3):156-62 [PMID: 25086658]
  46. Psychol Med. 2013 Nov;43(11):2339-47 [PMID: 23448697]
  47. J Nerv Ment Dis. 2003 Feb;191(2):87-92 [PMID: 12586961]
  48. Br J Psychiatry. 2021 Oct 06;:1-9 [PMID: 35049488]
  49. Schizophr Res. 2000 Sep 29;45(1-2):11-20 [PMID: 10978868]
  50. Front Psychol. 2014 Aug 12;5:881 [PMID: 25161641]
  51. Percept Mot Skills. 1971 Oct;33(2):575-81 [PMID: 5124116]
  52. Aust N Z J Psychiatry. 1996 Oct;30(5):587-99 [PMID: 8902166]
  53. Schizophr Res. 2010 Oct;123(1):71-6 [PMID: 20580205]
  54. J Child Psychol Psychiatry. 2021 Mar;62(3):357-365 [PMID: 32559319]
  55. Schizophr Bull. 2013 Sep;39(5):1018-26 [PMID: 22927672]
  56. Am J Psychiatry. 2000 Nov;157(11):1858-63 [PMID: 11058486]
  57. Clin Psychol Rev. 2016 Jun;46:151-67 [PMID: 27216559]
  58. Schizophr Res. 2022 Aug;246:205-206 [PMID: 35809352]
  59. Psychiatry Investig. 2010 Jun;7(2):93-101 [PMID: 20577617]
  60. J Am Psychiatr Nurses Assoc. 2020 Nov/Dec;26(6):542-554 [PMID: 31578909]
  61. Aust N Z J Psychiatry. 2009 Feb;43(2):118-28 [PMID: 19153919]
  62. Front Psychiatry. 2020 Apr 29;11:307 [PMID: 32411023]
  63. Aust N Z J Psychiatry. 2008 Aug;42(8):678-85 [PMID: 18622775]
  64. JAMA Psychiatry. 2013 Jan;70(1):107-20 [PMID: 23165428]
  65. Curr Pharm Des. 2012;18(4):376-85 [PMID: 22239568]
  66. PLoS One. 2013;8(3):e58176 [PMID: 23469268]
  67. Schizophrenia (Heidelb). 2022 Apr 20;8(1):39 [PMID: 35853903]
  68. Mol Psychiatry. 2022 Mar;27(3):1490-1501 [PMID: 34782711]
  69. Epidemiol Psychiatr Sci. 2021 Jul 06;30:e53 [PMID: 34225831]
  70. Psychiatr Pol. 2012 Jan-Feb;46(1):95-107 [PMID: 23214153]
  71. Arch Clin Neuropsychol. 2010 May;25(3):157-73 [PMID: 20197297]
  72. Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71 [PMID: 16343296]
  73. Curr Opin Neurobiol. 2000 Apr;10(2):205-10 [PMID: 10753790]
  74. Psychol Med. 2023 Jan;53(2):305-319 [PMID: 36377500]
  75. Front Psychiatry. 2021 Sep 10;12:753317 [PMID: 34566732]
  76. Schizophr Bull. 2023 Jul 4;49(4):1007-1021 [PMID: 37402250]
  77. Neuropsychobiology. 2014;70(3):181-8 [PMID: 25377241]
  78. Int J Dev Neurosci. 2011 May;29(3):237-43 [PMID: 21111039]
  79. Psychiatr Pol. 2017 Apr 30;51(2):271-282 [PMID: 28581537]
  80. J Neuropsychiatry Clin Neurosci. 2010 Summer;22(3):304-12 [PMID: 20686137]
  81. Am J Psychiatry. 2008 May;165(5):579-87 [PMID: 18413704]
  82. Rev Psiquiatr Salud Ment. 2016 Apr-Jun;9(2):78-86 [PMID: 26655378]
  83. Schizophr Res. 2009 Nov;115(1):82-7 [PMID: 19775869]
  84. Aust Occup Ther J. 2009 Aug;56(4):220-8 [PMID: 20854522]
  85. Am J Psychiatry. 2000 Sep;157(9):1416-22 [PMID: 10964857]
  86. JAMA Psychiatry. 2019 Feb 1;76(2):180-189 [PMID: 30484818]
  87. Eur Neuropsychopharmacol. 2014 Nov;24(11):1767-72 [PMID: 25219937]
  88. Schizophr Res. 2022 Jan;239:55-82 [PMID: 34844096]
  89. Psychiatry Investig. 2018 Oct;15(10):945-955 [PMID: 30223641]
  90. Can J Psychiatry. 2014 Jan;59(1):13-7 [PMID: 24444319]
  91. Schizophr Bull. 2020 Jan 4;46(1):110-120 [PMID: 31219164]
  92. Schizophr Bull. 2016 May;42(3):652-65 [PMID: 26519952]
  93. Schizophr Bull. 2017 Jul 1;43(4):824-832 [PMID: 27590844]
  94. Am J Psychiatry. 1992 Sep;149(9):1148-56 [PMID: 1386964]
  95. Schizophr Bull. 1996;22(2):353-70 [PMID: 8782291]
  96. Adv Cogn Psychol. 2019 Nov 14;15(4):308-317 [PMID: 32499840]
  97. Appl Neuropsychol. 2002;9(2):106-9 [PMID: 12214820]
  98. Schizophr Res. 2012 Dec;142(1-3):108-15 [PMID: 23025995]
  99. Isr J Psychiatry Relat Sci. 2014;51(1):54-62 [PMID: 24858635]
  100. Front Psychiatry. 2021 Mar 29;12:611069 [PMID: 33854448]
  101. Psychiatry Res. 2015 Jan 30;225(1-2):50-57 [PMID: 25453635]
  102. Front Psychiatry. 2013 Jun 24;4:35 [PMID: 23805107]
  103. Psychol Med. 2007 Oct;37(10):1377-91 [PMID: 17335638]
  104. Schizophr Res Cogn. 2019 Apr 05;17:100137 [PMID: 31024800]
  105. Arch Gen Psychiatry. 2012 Jun;69(6):562-71 [PMID: 22664547]
  106. Neurosci Biobehav Rev. 2021 Jul;126:329-337 [PMID: 33757817]
  107. Eur Psychiatry. 2015 Nov;30(8):943-9 [PMID: 26647870]
  108. Psychol Med. 2021 Jan;51(1):147-157 [PMID: 31713511]
  109. Schizophr Res. 2010 Jun;119(1-3):258-65 [PMID: 20347272]
  110. Early Interv Psychiatry. 2022 Sep;16(9):958-978 [PMID: 34904353]
  111. Schizophr Res. 2006 May;84(1):57-66 [PMID: 16630707]
  112. JMIR Ment Health. 2022 Nov 23;9(11):e37394 [PMID: 36416883]
  113. J Psychiatr Res. 2012 Jan;46(1):105-10 [PMID: 22056319]
  114. BMC Psychiatry. 2018 Jun 28;18(1):214 [PMID: 29954377]
  115. Schizophr Res. 2019 Apr;206:67-74 [PMID: 30558978]
  116. J Affect Disord. 2013 Feb 20;145(2):156-64 [PMID: 22877965]

Grants

  1. 2016/21/B/HS6/03210/National Science Center

Word Cloud

Created with Highcharts 10.0.0=0SOFASβfunctioningscoreCAARMSII-0TMTrelatedpsychosiselevatedPLEscognitivebiasessocio-occupational<001studywhetherTrailMakingTestassociatedseveritysymptomsamongyoungadultslevelpsychotic-likeexperiencesmediatedsubjectsDACOBSscalemeasurementstimelowerpredictedhigheraiminvestigateperformancepsychopathologicalrelationshiptotal187largerpopulation6722participated1-yearfollow-upinclusioncriteriahighestProdromalQuestionnairelackschizophreniadiagnosisEventually134716%completedwellbaselineexaminedtwiceusingpsychopathologyscalesfirstsecondcalculatedeffectsindicateindirect-onlymediationsexplained3538%varianceBexecutionpositively19028negatively37200165061SubtleEFdysfunctionsmaytranslategreaterpeopledeteriorationmetacognitionCognitiveBiasesSocio-OccupationalFunctioningMediateRelationshipExecutiveFunctionsSeverityPsychopathologyYoungAdultsPsychotic-likeExperiences:1-YearFollow-UpStudyexecutivefunctionsrisksocialoccupational

Similar Articles

Cited By

No available data.